Recent research indicates that disialoganglioside GD2 is aberrantly expressed in NSCLC, and its expression can be upregulated by the oral EZH2 inhibitor Tazemetostat, enhancing responsiveness to chimeric antigen receptor (CAR) T-cell therapy 23. The gene discussed is EZH2; the disease is non-small cell lung carcinoma.